



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

20 February 2012
EMA/807846/2011
Human Medicines Development and Evaluation

Addendum to public declaration of interests and confidentiality undertaking of the European network of paediatric research at the European Medicines Agency (Enpr-EMA) members relating to research interests

Please sign and date. If the document is completed by hand, please ensure that the information required is clearly readable (capital letters).

Public Declaration of Research Interests

I, Dr Gareth Veal

Nationality: UK

Organisation/company: Newcastle University

Professional address: Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne. NE2 4HH UK

Email address: G.J.Veal@ncl.ac.uk

do hereby declare on my honor that, to the best of my knowledge, the only research interests I have are those listed below (Please tick all boxes):



Current research interests and/or research completed in the past 12 months.

Please use additional pages if required by copying and pasting the text-boxes and check-boxes below. You will need to **protect the form** to enable proper use of boxes (fields); to do this you should view toolbar called "Forms", then click on the locking symbol named "Protect Form", and only then start typing entries into boxes.

Research title: **Pilot study to investigate the feasibility of 13-cis-retinoic acid pharmacokinetic monitoring in high-risk neuroblastoma patients**

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
☐	☐	☒	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	☐	☒	☐	☐	☐

Research title: **Investigating the clinical significance of pharmacogenetic factors affecting actinomycin D metabolism and drug transport in children with cancer**

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
☒	☐	☒	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	☐	☒	☒	☐	☐

Research title: Clinical pharmacology studies with dexamethasone in childhood acute lymphoblastic leukaemia.

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
☐	☐	☒	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	☐	☒	☒	☐	☐

Research title: CYP3A5 genotype as a potential risk factor for the development of ifosfamide nephrotoxicity in children

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
☐	☐	☒	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	☐	☒	☐	☐	☐

Research title: Pharmacokinetics of anticancer drugs in high-risk neuroblastoma

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
☐	☐	☒	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	☐	☒	☐	☐	☐

Research title: **Pharmacokinetics and pharmacogenetics of anticancer drugs in infants and young children**

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
☐	☐	X	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	☐	X	☐	☐	☐

Research title: **O3K trial - Pharmacokinetics and safety of a soluble tablet formulation of cyclophosphamide in children with cancer**

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
☐	☐	X	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	X	☐	☐	X	☐

Research title: **Retinoic acid metabolism and the development of CYP26 inhibitors as cancer therapeutics**

Category: (Please tick all that apply)

Basic / translational	Non-clinical	Clinical	Epidemiology	Methodological	Pharmacovigilance	Education/ Training
X	☐	☐	☐	☐	☐	☐

Funding: (Please tick all that apply)

Industry	European Commission	Medical research charity (not for profit organization):	National grant	International grant	Other (if so please describe)
☐	☐	X	X	☐	☐

Scientific publications: (Most relevant in past 3 years; maximum 5)

1. **Veal, GJ, Nguyen, L, Paci, A, Riggi, M, Amiel, M, Valteau-Couanet, D, Brock, P, Ladenstein, R, Vassal, G. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer 2012 (In press; doi: 10.1016/j.ejca.2012.05.020)**
2. **Veal, GJ, Boddy AV. Chemotherapy in newborns and preterm babies. Semin Fetal Neonatal Med 2012 17:243-248**
3. **Chinnaswamy, G, Errington, J, Foot, A, Boddy, AV, Veal, GJ, Cole, M. Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy. Eur J Cancer 2011 47: 1556-1563**
4. **Veal, GJ, Cole, M, Errington, J, Pearson, ADJ, Gerrard, M, Whyman, G, Ellershaw, C and Boddy, AV. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemother Pharmacol 2010 65: 1057-1066**
5. **Veal, GJ, Hartford, CM and Stewart, CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 2010 28: 4790-4799**

Signature:*Gareth J. Veal*..... **Date (DD/MM/YY):**11/07/12.....